Literature DB >> 2670438

Cadaveric renal transplantation under the American organ allocation system.

R Shapiro1, A G Tzakis, T R Hakala, W Lopatin, S Mitchell, B Koneru, A Stieber, R D Gordon, T E Starzl.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2670438      PMCID： PMC2952467          DOI： 10.1159/000416901

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  14 in total

1.  Renal Transplantation in the Presence of a Positive Cytotoxic Antibody.

Authors:  A Tzakis; T Hakala; L Makowka; R Duquesnoy; R Gordon; G Ambrosino; T E Starzl
Journal:  Transplant Proc       Date:  1988-02-01       Impact factor: 1.066

2.  A multifactorial system for equitable selection of cadaver kidney recipients.

Authors:  T E Starzl; T R Hakala; A Tzakis; R Gordon; A Stieber; L Makowka; J Klimoski; H T Bahnson
Journal:  JAMA       Date:  1987-06-12       Impact factor: 56.272

3.  Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY).

Authors:  T E Starzl; K A Porter; G Andres; C G Halgrimson; R Hurwitz; G Giles; P I Terasaki; I Penn; G T Schroter; J Lilly; S J Starkie; C W Putnam
Journal:  Ann Surg       Date:  1970-09       Impact factor: 12.969

4.  Cyclosporine immunosuppression and delayed graft function in 455 cadaveric renal transplants.

Authors:  R J Taylor; M D Landreneau; L Makowka; T J Rosenthal; R D Gordon; A G Tzakis; T E Starzl; T R Hakala
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

5.  The use of low-dose cyclosporine A in combination with azathioprine and steroids in renal transplantation.

Authors:  M Slapak; T Geoghegan; N Digard; K Ahmed; V L Sharman; R Crockett
Journal:  Transplant Proc       Date:  1987-04       Impact factor: 1.066

6.  Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone.

Authors:  R L Simmons; D M Canafax; M Strand; N L Ascher; W D Payne; D E Sutherland; J S Najarian
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

7.  Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.

Authors:  T E Starzl; M A Nalesnik; K A Porter; M Ho; S Iwatsuki; B P Griffith; J T Rosenthal; T R Hakala; B W Shaw; R L Hardesty
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

8.  An improved technique for multiple organ harvesting.

Authors:  T E Starzl; C Miller; B Broznick; L Makowka
Journal:  Surg Gynecol Obstet       Date:  1987-10

9.  A flexible procedure for multiple cadaveric organ procurement.

Authors:  T E Starzl; T R Hakala; B W Shaw; R L Hardesty; T J Rosenthal; B P Griffith; S Iwatsuki; H T Bahnson
Journal:  Surg Gynecol Obstet       Date:  1984-03

10.  Orthotopic heart and combined heart and lung transplantation with cyclosporin-A immune suppression.

Authors:  B A Reitz; C P Bieber; A A Raney; J L Pennock; S W Jamieson; P E Oyer; E B Stinson
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066
View more
  3 in total

1.  Renal transplantation in black recipients at the University of Pittsburgh.

Authors:  R Shapiro; A G Tzakis; T R Hakala; W B Lopatin; A C Stieber; T E Starzl
Journal:  Transplant Proc       Date:  1989-12       Impact factor: 1.066

2.  Cadaveric renal transplantation at the University of Pittsburgh: a two and one-half-year experience with the point system.

Authors:  R Shapiro; A G Tzakis; T R Hakala; W Lopatin; S Mitchell; B Koneru; A Stieber; R D Gordon; T E Starzl
Journal:  Clin Transpl       Date:  1988

3.  A prospective, randomized trial of FK-506 in renal transplantation--a comparison between double- and triple-drug therapy.

Authors:  R Shapiro; M Jordan; V Scantlebury; C Vivas; J Fung; J McCauley; A Tzakis; P Randhawa; A J Demetris; W Irish
Journal:  Clin Transplant       Date:  1994-12       Impact factor: 2.863
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.